Adherence to Performance Measures and Outcomes among Men Treated for Prostate Cancer

被引:14
|
作者
Schroeck, Florian R. [1 ,2 ]
Kaufman, Samuel R. [1 ]
Jacobs, Bruce L. [4 ]
Skolarus, Ted A. [1 ,2 ,3 ]
Miller, David C. [1 ,2 ]
Montgomery, Jeffrey S. [2 ]
Weizer, Alon Z. [2 ]
Hollenbeckt, Brent K. [1 ,2 ]
机构
[1] Univ Michigan, Dept Urol, Div Hlth Serv Res, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Urol, Div Urol Oncol, Ann Arbor, MI 48109 USA
[3] Vet Affairs Ann Arbor Healthcare Syst, Ctr Clin Management Res, Hlth Serv Res & Dev Serv, Ann Arbor, MI USA
[4] Univ Pittsburgh, Sch Med, Dept Urol, Pittsburgh, PA USA
来源
JOURNAL OF UROLOGY | 2014年 / 192卷 / 03期
关键词
prostate; prostatic neoplasms; quality of health care; SEER program; Medicare; QUALITY-OF-CARE; RADICAL PROSTATECTOMY; INDICATORS; HOSPITALS;
D O I
10.1016/j.juro.2014.03.091
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We assessed the relationship between health care system performance on nationally endorsed prostate cancer quality of care measures and prostate cancer treatment outcomes. Materials and Methods: This retrospective cohort study included 48,050 men from SEER-Medicare linked data diagnosed with localized prostate cancer between 2004 and 2009, and followed through 2010. Based on a composite quality measure we categorized the health care systems in which these men were treated into 1-star (bottom 20%), 2-star (middle 60%) and 3-star (top 20%) systems. We then examined the association of health care system level quality of care with outcomes using multivariable logistic and Cox regression. Results: Patients who underwent prostatectomy in 3-star vs 1-star health care systems were at lower risk for perioperative complications (OR 0.80, 95% CI 0.64-1.00). However, they were more likely to undergo a procedure addressing treatment related morbidity, eg for sexual morbidity (11.3% vs 7.8%, p - 0.043). In patients who received radiotherapy star ranking was not associated with treatment related morbidity. In all patients star ranking was not significantly associated with all-cause mortality (HR 0.99, 95% CI 0.84-1.15) or secondary cancer therapy (HR 1.04, 95% CI 0.91-1.20). Conclusions: We found no consistent association between health care system quality and outcomes, which questions how meaningful these measures ultimately are for patients. Thus, future studies should focus on developing more discriminative quality measures.
引用
收藏
页码:743 / 748
页数:6
相关论文
共 50 条
  • [41] Increasing Use of Observation among Men at Low Risk for Prostate Cancer Mortality
    Ritch, Chad R.
    Graves, Amy J.
    Keegan, Kirk A.
    Ni, Shenghua
    Bassett, Jeffrey C.
    Chang, Sam S.
    Resnick, Matthew J.
    Penson, David F.
    Barocas, Daniel A.
    JOURNAL OF UROLOGY, 2015, 193 (03): : 801 - 806
  • [42] Racial Differences in the Impact of Comorbidities on Survival Among Elderly Men With Prostate Cancer
    Putt, Mary
    Long, Judith A.
    Montagnet, Chantal
    Silber, Jeffrey H.
    Chang, Virginia W.
    Liao, Kaijun
    Schwartz, J. Sanford
    Pollack, Craig Evan
    Wong, Yu-Ning
    Armstrong, Katrina
    MEDICAL CARE RESEARCH AND REVIEW, 2009, 66 (04) : 409 - 435
  • [43] Transperineal Prostate Biopsy Improves the Detection of Clinically Significant Prostate Cancer among Men on Active Surveillance
    Abouassaly, Robert
    JOURNAL OF UROLOGY, 2021, 205 (04): : 1074 - 1074
  • [44] Comorbidity and Competing Risks for Mortality in Men With Prostate Cancer
    Daskivich, Timothy J.
    Chamie, Karim
    Kwan, Lorna
    Labo, Jessica
    Dash, Atreya
    Greenfield, Sheldon
    Litwin, Mark S.
    CANCER, 2011, 117 (20) : 4642 - 4650
  • [45] Patterns and Correlates of Prostate Cancer Treatment in Older Men
    Roberts, Calpurnyia B.
    Albertsen, Peter C.
    Shao, Yu-Hsuan
    Moore, Dirk F.
    Mehta, Amit R.
    Stein, Mark N.
    Lu-Yao, Grace L.
    AMERICAN JOURNAL OF MEDICINE, 2011, 124 (03): : 235 - 243
  • [46] Testosterone Therapy in Patients with Treated and Untreated Prostate Cancer: Impact on Oncologic Outcomes
    Ory, Jesse
    Flannigan, Ryan
    Lundeen, Colin
    Huang, James G.
    Pommerville, Peter
    Goldenberg, S. Larry
    JOURNAL OF UROLOGY, 2016, 196 (04): : 1082 - 1088
  • [47] Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis
    Raval, A. D.
    Thakker, D.
    Vyas, A.
    Salkini, M.
    Madhavan, S.
    Sambamoorthi, U.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2015, 18 (02) : 110 - 121
  • [48] Sharp Decline In Prostate Cancer Treatment Among Men In The General Population, But Not Among Diagnosed Men
    Borza, Tudor
    Kaufman, Samuel R.
    Shahinian, Vahakn B.
    Yan, Phyllis
    Miller, David C.
    Skolarus, Ted A.
    Hollenbeck, Brent K.
    HEALTH AFFAIRS, 2017, 36 (01) : 108 - 115
  • [49] Prostate cancer outcomes among older men: insurance status comparisons results from CaPSURE database
    N Sadetsky
    E P Elkin
    D M Latini
    J DuChane
    P R Carroll
    Prostate Cancer and Prostatic Diseases, 2008, 11 : 280 - 287
  • [50] Prostate cancer outcomes among older men: insurance status comparisons results from CaPSURE database
    Sadetsky, N.
    Elkin, E. P.
    Latini, D. M.
    DuChane, J.
    Carroll, P. R.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2008, 11 (03) : 280 - 287